Comparing the current results to its competitors, 4d Molecular Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 25106.67 % year on year. The sales growth was above 4d Molecular Therapeutics Inc 's competitors' average revenue growth of 163.67 %, achieved in the same quarter.
Due to outstanding performance in Overall company, revenue grew by 25106.67 % 4d Molecular Therapeutics Inc improved its market share, to approximately 0.58 %.
August 27, 2024
Emeryville, Calif. August 27, 2024 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading clinical-stage genetic medicines company, has announced its plans to host a 4D-150 Wet AMD Development Day on September 18, 2024, at 4:15 p.m. ET. This significant event underscores 4DMT s commitment to advancing innovative genetic treatments for large market diseases, particularly through its promising candidate, 4D-150, aimed at treating wet age-related macular degeneration (wet AMD).This upcoming Development Day will serve as a deep dive into the progress and future prospects of 4D-150, a cutting-edge intravitreal gene therapy. Wet AMD is a prevalent and severe eye condition that causes vision l...
May 30, 2024
4D Molecular Therapeutics (4DMT), a renowned genetic medicines company, has recently shared exciting news about the interim data from its Phase 1/2 AEROW clinical trial for aerosolized 4D-710, a potential breakthrough treatment for cystic fibrosis (CF) lung disease. The company announced that the data will be presented at the upcoming 47th European Cystic Fibrosis Conference taking place in Glasgow, UK. This highly anticipated presentation will shed light on the potential of 4D-710 to revolutionize the treatment landscape for CF patients. In addition, 4DMT will organize a webcast to discuss the details of the data and provide an update on their program.Background:Cystic fibrosis is a life-threatening genetic...
March 28, 2024
In recent years, genetic medicine has emerged as a groundbreaking field in the fight against numerous diseases. Among these diseases, Cystic Fibrosis (CF) has posed significant challenges due to its complex genetic nature. However, there is a new ray of hope with the development of 4D-710, an aerosolized genetic medicine by 4D Molecular Therapeutics (4DMT). The company has recently provided an update on its regulatory interactions and development path for this promising treatment, indicating exciting progress in tackling CF lung disease.4D-710: A Glimpse into the Future of CF Treatment:4D-710 is an aerosolized genetic medicine specifically engineered to target and correct the underlying genetic mutations res...
February 12, 2024
4D Molecular Therapeutics (4DMT), a pioneering clinical-stage genetic medicines company, shared updated interim safety and efficacy data on their investigational therapy, 4D-310, for the treatment of Fabry disease cardiomyopathy. The data were presented at the prestigious WORLD Symposium 2024 in San Diego, California. Fabry disease is a rare genetic disorder characterized by the accumulation of a lipid called globotriaosylceramide (GL-3) within various organs, leading to life-threatening complications.Promising Results for Fabry Disease Cardiomyopathy Treatment:The study included six adult patients with Fabry disease cardiomyopathy who received a single intravenous infusion of 4D-310 at a dose of 1E13 vector...
Jasper Therapeutics Inc operates in the biotechnology industry, focusing on developing stem cell-based therapies for hematopoietic and immune system disorders. Their business model involves utilizing innovative stem cell technologies and partnerships within the medical community to advance their research and bring potential treatments to patients in need.
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Sources:
4d Molecular Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on 4d Molecular Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
